DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMA
Biogen announced it intends to initiate a global phase 3b study to investigate clinical outcomes and safety of a higher dose of Spinraza in patients with later onset spinal muscular atrophy previously treated with Evrysdi.
“We believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with Evrysdi [risdiplam, Roche],” Maha Radhakrishnan, MD, chief medical officer at Biogen, said in a press release. “The ASCEND study seeks to understand if [Spinraza (nusinersen, Biogen)] may address that unmet medical need and will help inform the future of [spinal muscular atrophy (SMA)] treatment, with the hope of improving patients’ outcomes for the long term.”
Data from prior studies suggested risdiplam exposure decreases as age and weight increase, with adults exhibiting an approximate 40% reduction in drug concentration compared with infants. Upon a patient reaching 20 kg, risdiplam’s dosing is capped at 5 mg.
Related Content
-
EducationSpinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
-
People & PlacesStanford Healthcare – Spinal Muscular AtrophyStanford Neuromuscular Program has exten...
-
EducationNeurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
EducationImprovement in Fine Manual Dexterity in Children With Spinal Muscular Atrophy Type 2 After Nusinersen Injection: A C...Although nusinersen has been demonstrate...
-
EducationComparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
-
EducationNonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
EducationReal-World Safety of Nusinersen in Japan: Results From an Interim Analysis of a Post-Marketing Surveillance and Safe...Purpose: Nusinersen is the first disease...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email